breathing techniques (CMBT) on stress and exercise induced high blood pressure (BP). CMBT was performed according to the christian tradition.
Introduction: Most patients with hypertension, in most countries, remain poorly controlled despite high health care costs. One intervention which may improve blood pressure control at minimal cost is greater patient involvement in their own care. The Targets and Self Monitoring in Hypertension (TASMINH) study was the first UK randomised controlled trial of patient self monitoring in hypertension and the first anywhere to evaluate self monitoring in a community clinic setting.
Method: 441 people receiving treatment in primary care for high blood pressure but not controlled below target (Ͼ139/84 mmHg) were randomised between intervention and usual care. Patients in the intervention group received treatment targets along with facilities to measure their blood pressure in the practice waiting room. They were asked to vary follow up with the Primary Care Physician / Practice Nurse depending on whether or not their blood pressure was below target. The primary outcome was change in systolic blood pressure (SBP) at six months and one year and the study was powered to detect a 5 mmHg difference. Cost data were collected in parallel to trial outcome data.
Results: 400 (91%) of patients attended follow up at 1 year. There was a significant reduction in systolic blood pressure in the intervention group compared to usual care after six months (mean difference in SBP 4.3 mmHg (95% CI 0.8, 7.9)) but not one year (mean difference in SBP 2.7 mmHg ( 95% CI -1.2, 6.6)). No difference was seen in diastolic blood pressure, anxiety, explanatory health behaviours or number of prescribed medication. Patients who self monitored lost more weight than control, rated self monitoring above professional monitoring and attended professionals less often. Self monitoring did not cost significantly more than standard care: incremental cost effectiveness ratio $9.76 /mmHg (95% CI -13.78, 36.55).
Conclusion:
Practice based self monitoring resulted in small but significant improvements of blood pressure at six months which were not sustained after a year. Self monitoring was well received by patients, there was no increase in anxiety and no additional cost. Practice based self monitoring is feasible, cost effective and results in equivalent control to usual care.
Key Words: Hypertension, Primary Care / Family Practice, Self Management F Messerli, G Bakris, D Bell, V Fonseca, R Katholi, J McGill, R Phillips, P Raskin, J Wright, Jr, M Lukas, K Anderson, F Holdbrook. Cardiology, St Lukes-Roosevelt Hospital Center, New York, NY; Chicago, IL; Birmingham, AL; New Orleans, LA; Springfield, IL; St Louis, MO; New York, NY; Dallas, TX; Cleveland, OH; Philadelphia, PA. Being overweight is a common complication of hypertensive cardiovascular disease and diabetes (DM). Drugs that promote weight gain or make it difficult to lose weight are a concern in susceptible patients (pts). Beta-blocker therapy causes a systematic weight gain of over 1 kilogram on average (Sharma et al. Hypertension 2001; 37:50) .
P-234 WEIGHT CHANGES AND INSULIN SENSITIVITY-NOT ALL BETA-BLOCKERS ARE CREATED EQUAL
In the prospective double-blind, randomized GEMINI study, pts with DM and SBP Ͼ130 to Ͻ179 mmHg and DBP Ͼ80 to Ͻ109 mmHg on ACE/ARB, were randomized to carvedilol (C) 6.25-25 mg bid (nϭ498) or metoprolol tartrate (M) 50-200 mg bid (nϭ737), and followed for 5 months. No significant associations were seen between change from BL in HbA1c, HOMA-IR, SBP, or DBP and weight change. We previously reported improvements in insulin sensitivity and glycemic control with C, but not with M (Bakris et al. JAMA 2004; 292:2227) . Weight changes in pts taking C vs M may, at least to some extent, account for the beneficial effects on glycemic control. The changes in insulin sensitivity may be independent of weight and due to inherent drug effect. Most hypertensive patients require 2 or more drugs to achieve target blood pressure. Results of the ALLHAT trial indicate that diuretic-based antihypertensive regimens are effective in reducing cardiovascular morbidity and mortality. The ATTACH trial evaluated 3 dose levels of hydrochlorothiazide (HCT) (6.25 mg, 12.5 mg and 25 mg), 4 levels of metoprolol succinate extended release (Toprol-XL) (25 mg, 50 mg, 100 mg and 200 mg), 9 of the possible combinations and placebo in an 8 week, multicenter, randomized, double-blind unbalanced factorial trial in patients with essential hypertension (DBP Ͼ 95, Ͻ 114 mm Hg; SBPϽ180 mm Hg).
The investigators randomized 1571 patients; 51% were male, 16% were Ͼ 65 years of age and 25% were black. Mean baseline blood pressure was 151/100 mm Hg.
Blood pressure declined significantly relative to placebo (pϽ0.05) with all combinations (placebo-subtracted range SBP/DBPϭ 6.1/3.9 to 15.9/12.2 mm Hg) (Figure) . Each component contributed to the effect of the combination for both DBP (T-AVE p ϭ 0.0015) and SBP (T-AVE pϭ0.0006).
Forty-six (2.9%) patients discontinued for adverse events but there was no clustering of events in any one treatment group. Serum potassium declined with HCT and was related to dose.
Toprol-XL-HCT is an effective antihypertensive combination agent over the range of doses (HCT 6.25 mg to 25 mg; Toprol-XL 25 mg to 200 mg).
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P-238 HEART RATE VARIABILITY AND ECG CHANGES IN 148 DANISH PATIENTS AFTER TWO YEARS IN THE VALUE TRIAL
Ole L Pedersen, Jens Refsgaard, Eric S Nielsen. Department of Medicine, Viborg Hospital, Viborg, Denmark. Background: Modulation of the autonomic nervous system through an increase in heart rate variability (HRV) with potential benefits in reducing the risk of ventricular arrhythmias has been demonstrated earlier in ischaemic heart disease with drugs affecting the renin-angiotensin system. The VALUE-trial explored the possible cardiac benefits of a valsartan-based (VAL) regimen compared to treatment with amlodipine (AML) in high-risk hypertensive patients. The purpose of the present substudy was to evaluate the treatment effects on the ECG and HRV calculated from ambulatory electrocardiographic recordings obtained by Holter technique during 24 hours.
Methods: Nine Danish VALUE-centres with a total of 148 patients participated in this substudy. Holter-recordings (2-channel Tracker, Reynolds Pathfinder analysis) were obtained after two years of maintained randomized therapy. From Holter data ventricular arrhythmias were classified according to severity and from 2-hours periods during day and night, time domain HRV measures were derived.
Results: The demographics showed two well-balanced groups with equal blood pressure reduction to 140/80 mmHg. Potassium levels were equal (VAL 4.1 Ϯ0.4 vs. 3.9 Ϯ0.4 mmol/L, ns). Beta-blockers were given as add-on to 37% in both groups. After 2 years the measured ECG criteria for left ventricular hypertrophy and the levels of QTc (VAL 406 Ϯ25 vs. 413 Ϯ27 msec, ns) and QT-dispersion (VAL 35 Ϯ17 vs. 38 Ϯ15 msec, ns) were equal.in the two groups. The long term HRV measured as the standard deviation of the average normal to normal intervals (SDANN) was significantly higher in VAL compared with AML during the night (38 Ϯ17 vs. 32 Ϯ13 msec, Pϭ0.019), whereas the SDANN did not differ between the two groups in the daytime. The 24 hour triangular index was significantly higher in VAL compared with AML (32 Ϯ11 vs. 28 Ϯ9, Pϭ0.02). The prevalence of all categories of ventricular arrhythmia as well as the prevalence of atrial fibrillation was equal in the two groups.
Conclusion: Two indices of long-term HRV showed differences in favour of the VAL regimen. Although baseline HRV data were not obtained, the findings in this study substantiate correlation between a treatment regimen based on valsartan and alteration of the autonomic cardiovascular control through an increase of HRV.
